Submitted:
26 May 2026
Posted:
27 May 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Exclusion Criteria
2.3. Ethics
2.4. Follow-Up and Weight Reduction Program
2.5. Body Mass Index Measurements
2.6. Specimen Collection and Processing
2.7. Data Analysis
3. Results
| Parameters | BMI | |
|---|---|---|
| Pearson correlation (r) | P-value | |
| Body weight (kg) | 0.934* | 0.001 |
| Waist circumferences (cm) | 0.466* | 0.001 |
| Vaspin (pg/ml) | 0.262* | 0.003 |
| Insulin (ng/ml) | 0.013 | 0.885 |
| FBS (mg/dl) | 0.461* | 0.001 |
| TG (mg/dl) | 0.179* | 0.043 |
| Cholesterol (mg/dl) | 0.312* | 0.001 |
| LDL (mg/dl) | 0.286* | 0.001 |
| HDL (mg/dl) | -0.266* | 0.002 |
4. Discussion
5. Conclusions
Clinical Trial Number
Code Availability
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of interest
References
- Riaz, M.; Lodhi, S. Beyond BMI: Exploring obesity trends in the South Asian region. Obes. Pillars 2025, 13, 100156. [Google Scholar] [CrossRef]
- Wang, L. Obesity and its comorbidities: current treatment options, emerging biological mechanisms, future perspectives and challenges. Diabetes Metab. Syndr. Obes. 2025, 3427–3445. [Google Scholar] [CrossRef]
- Hildebrand, S.; Pfeifer, A. The obesity pandemic and its impact on non-communicable disease burden. Pflügers Arch.-Eur. J. Physiol. 2025, 477(5), 657–668. [Google Scholar] [CrossRef]
- Younis, J. Prevalence of overweight, obesity, and associated factors among healthcare workers in the Gaza Strip, Palestine: A cross-sectional study. Front. Public Health 2023, 11, 1129797. [Google Scholar] [CrossRef]
- Keller, K. Increasing Obesity Rates Worldwide from 1976 to 2016: The Obesity Epidemic. J. Clin. Med. 2026, 15(1), 394. [Google Scholar] [CrossRef]
- WHO. World Health Organization, Fact Sheet: Obesity and overweight. 2026 8 December 2025. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
- Abdelgadir, E. Prevalence of overweight and obesity in adults from the Middle East: A large-scale population-based study. Diabetes Obes. Metab. 2025, 27(7), 3676–3685. [Google Scholar] [CrossRef] [PubMed]
- Al-Suhaimi, E.A. Adipose tissue as an endocrine organ and a glance on local hormones, in Emerging Concepts in Endocrine Structure and Functions; Springer, 2022; pp. 349–392. [Google Scholar]
- Aruwa, C.E.; Sabiu, S. Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics. Heliyon 2024, 10(1). [Google Scholar] [CrossRef] [PubMed]
- Fathey, H. Visceral Adipose Tissue-Derived Serine Protease Inhibitor (VASPIN) as A Prognostic Marker in Systemic Hypertension. Egypt. J. Hosp. Med. 2022, 86(1), 877–881. [Google Scholar] [CrossRef]
- Liu, S. Effects of vaspin on pancreatic β cell secretion via PI3K/Akt and NF-κB signaling pathways. PLoS ONE 2017, 12(12), e0189722. [Google Scholar] [CrossRef] [PubMed]
- Pilarski, Ł. Association of serum vaspin concentration with metabolic disorders in obese individuals. Biomolecules 2023, 13(3), 508. [Google Scholar] [CrossRef]
- Kim, J.M.; Kim, T.N.; Won, J.C. Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab. Syndr. Relat. Disord. 2013, 11(6), 385–391. [Google Scholar] [CrossRef]
- Suder, A. Effects of exercise and dietary interventions on asprosin, leptin, and lipid metabolism in males with abdominal obesity, a randomized controlled trial. Sci. Rep. 2024, 14(1), 28109. [Google Scholar] [CrossRef]
- Tok, Ö. Effects of increased physical activity and/or weight loss diet on serum myokine and adipokine levels in overweight adults with impaired glucose metabolism. J. Diabetes Its Complicat. 2021, 35(5), 107892. [Google Scholar] [CrossRef]
- Youn, B.-S. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57(2), 372–377. [Google Scholar] [CrossRef] [PubMed]
- Sacks, D.B. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 2002, 48(3), 436–472. [Google Scholar] [CrossRef]
- Barham, D.; Trinder, P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972, 97(1151), 142–145. [Google Scholar] [CrossRef]
- Jacobs, D.S.; et al. Laboratory test handbook; Lexi-Comp Incorporated, 1996. [Google Scholar]
- Fossati, P.; Prencipe, L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 1982, 28(10), 2077–2080. [Google Scholar] [CrossRef]
- Grove, T.H. Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium. Clin. Chem. 1979, 25(4), 560–564. [Google Scholar] [CrossRef] [PubMed]
- Jakicic, J.M. Role of physical activity and exercise in treating patients with overweight and obesity. Clin. Chem. 2018, 64(1), 99–107. [Google Scholar] [CrossRef] [PubMed]
- Ross, R. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020, 16(3), 177–189. [Google Scholar] [CrossRef]
- Jaffar, A. Biochemical Characterization of Novel Adipokines and Their Physiological Role in Insulin Sensitivity: A Systematic Review: Novel Adipokines and Their Physiological Role in Insulin Sensitivity. Pak. J. Health Sci. 2026, 178–186. [Google Scholar] [CrossRef]
- Oberbach, A. Serum vaspin concentrations are decreased after exercise-induced oxidative stress. Obes. Facts 2010, 3(5), 328–331. [Google Scholar] [CrossRef]
- Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121), 840–846. [Google Scholar] [CrossRef] [PubMed]
- Qureshi, K.; Abrams, G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. WJG 2007, 13(26), 3540. [Google Scholar] [CrossRef]
- Grundy, S. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89(6), 2595–2600. [Google Scholar] [CrossRef] [PubMed]
- Enkhmaa, B. Lifestyle changes: effect of diet, exercise, functional food, and obesity treatment on lipids and lipoproteins. Endotext [Internet]. 2018.
- Zhao, X. The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 2023, 14, 1149239. [Google Scholar] [CrossRef] [PubMed]
| Parameter | Non-Obese female | Obese female | P-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 (3-months diet) |
Group 2 (6-months diet) |
Group 3 (> 6-months diet) |
||||||||
| N | % | N | % | N | % | N | % | |||
|
Age (years) |
20 – 27 | 22 | 34.4 | 18 | 28.1 | 14 | 21.9 | 8 | 12.5 | 0.053 |
| 28 – 35 | 20 | 31.3 | 12 | 18.8 | 20 | 31.3 | 20 | 31.2 | ||
| 36 – 43 | 16 | 25.0 | 24 | 37.5 | 24 | 37.5 | 30 | 46.9 | ||
| 44 – 50 | 6 | 9.3 | 10 | 15.6 | 6 | 9.3 | 6 | 9.4 | ||
| Mean ± SD | 31.60 ± 6.94 | 34.25 ± 9.14 | 34.34 ± 7.90 | 35.90 ± 5.82 | ||||||
| Marital status | Single | 8 | 12.5 | 22 | 34.4 | 18 | 28.1 | 10 | 15.6 | 0.155 |
| Married | 56 | 87.5 | 42 | 65.6 | 46 | 71.9 | 54 | 84.4 | ||
| Residency | North Gaza | 4 | 12.5 | 10 | 15.6 | 6 | 9.4 | 8 | 12.5 | 0.207 |
| Gaza | 22 | 34.4 | 26 | 40.6 | 12 | 18.8 | 30 | 46.9 | ||
| Middle area | 10 | 15.6 | 4 | 6.2 | 14 | 21.9 | 12 | 18.8 | ||
| Khan Younis | 14 | 21.9 | 12 | 18.8 | 26 | 40.6 | 6 | 9.4 | ||
| Rafah | 10 | 15.6 | 12 | 18.8 | 6 | 9.4 | 8 | 12.5 | ||
| Parameters | Non-Obese female | Aerobic-case groups (Obese female) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Group 1 (3-month diet) |
Group 2 (6-month diet) |
Group 3 (< 6-month diet) |
Change (%) |
P-value | |||||
| Before | After | Before | After | Before | After | ||||
| Height (m) | 1.62 ± 007 | 1.58 ± 0.05 | 1.58 ± 0.05 | 1.59 ± 0.07 | 1.59 ± 0.07 | 1.61 ± 0.9 | 1.61 ± 0.9 | 47.30 a 27.45 b 34.88 c | 0.028 0.166 0.612 |
| Weight (kg) | 61.4 ± 7.3 | 96.3 ± 17.3 | 90.4 ± 16.5 | 86.5 ± 14.2 | 78.2 ± 13.5 | 99.5 ± 15.6 | 82.8 ± 14.4 | 47.30 a 27.45 b 34.88 c | ≤0.001 |
| Mean weight Difference | 5.9 ± 3.4 decrease | 8.32 ± 6.0 decrease | 16.7 ± 8.4 decrease | ≤0.01 | |||||
|
Waist circumference (cm) |
76.4 ± 5.9 | 93.4 ± 11.8 | 91.3 ± 11.7 | 86.0 ± 9.8 | 83.3 ± 9.9 | 90.6 ± 11.3 | 85.0 ± 11.0 | 19.6 a 9.04 b 11.33 c |
≤0.001 |
| Mean WC Difference | 2.1 ± 1.1 decrease | 2.7 ± 1.2 decrease | 5.6 ± 1.4 decrease | ≤0.01 | |||||
| BMI (kg/m2) | 23.24 ± 1.4 | 38.51 ± 5.9 | 36.17 ± 5.8 | 33.98 ± 4.7 | 30.74 ± 4.8 | 38.59 ± 6.9 | 32.06 ± 5.9 | 55.64 a 32.27 b 37.95 c |
≤0.001 |
| Mean BMI Difference | 2.34 ± 1.3 decrease | 3.25 ± 2.2 decrease | 6.53 ± 3.49 decrease | ≤0.01 | |||||
| Parameter | Non-Obese female | Aerobic-case groups (Obese female) | ||||
|---|---|---|---|---|---|---|
| Group 1 (3-month diet) |
Group 2 (6-month diet) |
Group 3 (< 6-month diet) |
Change (%) |
P-value | ||
| Vaspin (pg/ml) | 61.02 ± 15.74 | 84.84 ± 33.35 | 80.14 ± 25.79 | 62.25 ± 19.0 | 39.04 31.33 2.02 |
*0.006 *0.01 0.853 |
| Insulin (ng/ml) | 5.73 ± 1.85 | 19.25 ± 1.59 | 16.46 ± 1.28 | 5.62 ± 0.91 | 235.95 187.26 1.92 |
*≤0.001 *≤0.001 0.488 |
| Glucose (mg/dl) | 76.31 ± 8.27 | 82.35 ± 10.51 | 78.41 ± 6.86 | 81.49 ± 11.96 | 7.92 2.75 6.79 |
*0.026 0.358 0.067 |
| Parameter | Non-Obese female | Aerobic-case groups (Obese female) | ||||
|---|---|---|---|---|---|---|
| Group 1 (3-month diet) |
Group 1 (6-month diet) |
Group 1 (>6-month diet) |
Change (%) |
P-value | ||
| TG (mg/dl) | 68.95 ± 27.65 | 85.48 ± 38.60 | 82.20 ± 38.93 | 78.22 ± 27.65 | 23.80 19.21 13.44 |
0.081 0.124 0.262 |
| TC (mg/dl) | 169.9 ± 25.48 | 185.47 ± 30.31 | 183.63 ± 38.04 | 178.4 ± 19.92 | 9.16 8.08 5.00 |
0.053 0.195 1.000 |
| LDL (mg/dl) | 111.40 ± 23.61 | 121.25 ± 28.50 | 117.80 ± 35.14 | 114.95 ± 17.92 | 8.84 5.75 3.19 |
0.184 0.437 0.511 |
| HDL (mg/dl) | 43.35 ± 11.27 | 42.25 ± 13.48 | 45.17 ± 12.95 | 46.59 ± 12.96 | -2.45 4.20 7.47 |
0.753 0.596 0.346 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).